Quarterly report pursuant to Section 13 or 15(d)

6. Commitments and Contingencies (Details Narrative)

v2.4.1.9
6. Commitments and Contingencies (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2014
Dec. 31, 2013
Mar. 31, 2014
Potential severance under certain employment agreements     $ 1,130,000us-gaap_SeveranceCosts1    
Aggregated annual salaries under certain employment agreements 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent   935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent    
Product revenue 2,651,000us-gaap_SalesRevenueGoodsNet 2,450,000us-gaap_SalesRevenueGoodsNet 8,142,000us-gaap_SalesRevenueGoodsNet 8,627,000us-gaap_SalesRevenueGoodsNet  
Product licensing fees 378,000us-gaap_LicensesRevenue 629,000us-gaap_LicensesRevenue 1,130,000us-gaap_LicensesRevenue 1,459,000us-gaap_LicensesRevenue  
Vetericyn and Innovacyn [Member]          
Product revenue 122,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
652,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
1,110,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
2,682,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
 
Accounts receivable 28,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
  28,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
  220,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
More Pharma [Member]          
Accounts receivable 609,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
  609,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
  790,000us-gaap_AccountsReceivableGross
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
Transaction costs 28,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
28,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
48,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
48,000us-gaap_RelatedPartyTransactionAmountsOfTransaction
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
 
Amortization of upfront fees (transaction costs) $ 378,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 379,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 1,130,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
$ 1,131,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember